Never-smokers with lung cancer

In the last few weeks, the flurry of posts on non-small cell lung cancer (NSCLC) have triggered some interesting responses and questions in my inbox.

Rather than try and answer them all, I came across this excellent presentation from Dr Sai-Hong Ignatius Ou, who is a lung cancer doctor at the University of Irvine in Southern California.  He summarises the issues surrounding EGFR inhibitors, which patients are most likely to respond, and why. 

It is an important topic to understand for doctors and patients because there are large pockets of Asian non-smokers in California (and elsewhere in the US) and these patients are most likely to have improved outcomes on erlotinib (Tarceva) or gefitinib (Iressa).

Take a look at his synopsis below.  If you like it, it can also be downloaded for later viewing:

Never-smoker with lung cancer in Southern California

View more presentations from Sai-Hong Ignatius Ou.

Related articles by Zemanta

• FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer (pharmastrategyblog.com)
• Strides Made in Lung Cancer Treatment (nlm.nih.gov)

Comments

[MaverickNY]

If any anyone is interested, here is the link to the good doctor at Irvine:

http://www.healthcare.uci.edu/spotlight.asp?filename=data/cancer_center/medical_oncology_services